-
公开(公告)号：US20140329798A1
公开(公告)日：2014-11-06
申请号：US14358241
申请日：2012-11-09
发明人： Scott Edmondson , Zhiyong Hu , Ping Liu , Gregori J. Morriello , Jason W. Szewczyk , Bowei Wang , Liping Wang , Harold B. Wood , Cheng Zhu , Yuping Zhu , Zhiqiang Guo
IPC分类号： C07D513/04 , C07D239/42 , C07D405/12 , C07D409/12 , C07D498/04 , C07D487/04 , C07D403/14 , C07D401/14 , C07D403/12 , C07D471/04
CPC分类号： C07D513/04 , C07D239/42 , C07D401/04 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04
摘要： Substituted cyclopropyl compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included
摘要翻译： 披露式（I）的取代的环丙基化合物及其药学上可接受的盐可用于治疗或预防2型糖尿病和类似病状。 该化合物可用作G蛋白偶联受体GPR-119的激动剂。 还包括药物组合物和治疗方法
-
公开(公告)号：US20210115044A1
公开(公告)日：2021-04-22
申请号：US17048811
申请日：2019-04-22
发明人： Tao Yu , James M. Apgar , Alan Whitehead , Yonglian Zhang , Zhiyong Hu , Valerie W. Shurtleff , John A. McCauley , Izzat T. Raheem
IPC分类号： C07D471/16 , A61K31/4985 , A61P31/18 , A61K31/52 , A61K31/435 , A61K31/5383 , A61K31/506 , A61K31/513 , A61K31/685 , A61K31/427
摘要： The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, R4, R5, R6 and n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
-
公开(公告)号：US20180009796A1
公开(公告)日：2018-01-11
申请号：US15104537
申请日：2015-01-20
发明人： Richard Berger , Timothy A. Blizzard , Brian T. Campbell , Helen Y. Chen , John S. Debenham , Sunita V. Dewnani , Byron Dubois , Candido Gude , Zack Zhiqiang Guo , Bart Harper , Zhiyong Hu , Songnian Lin , Ping Liu , Ming Wang , Feroze Ujjainwalla , Jiayi Xu , Libo Xu , Rui Zhang
IPC分类号： C07D413/14 , C07D417/14 , C07D413/12 , C07D471/04 , C07D401/12
CPC分类号： C07D413/14 , C07D401/12 , C07D401/14 , C07D413/12 , C07D417/14 , C07D471/04
摘要： The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.
-
公开(公告)号：US09018224B2
公开(公告)日：2015-04-28
申请号：US14358241
申请日：2012-11-09
发明人： Scott Edmondson , Zhiyong Hu , Ping Liu , Gregori J. Morriello , Jason W. Szewczyk , Bowei Wang , Liping Wang , Harold B. Wood , Cheng Zhu , Yuping Zhu , Zhiqiang Guo
IPC分类号： A01N43/54 , A61K31/505 , C07D513/04 , C07D401/14 , C07D405/14 , C07D413/14 , C07D401/04 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04 , C07D239/42 , C07D403/12 , C07D403/14 , C07D405/12 , C07D409/12
CPC分类号： C07D513/04 , C07D239/42 , C07D401/04 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04
摘要： Substituted cyclopropyl compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included.
摘要翻译： 披露式（I）的取代的环丙基化合物及其药学上可接受的盐可用于治疗或预防2型糖尿病和类似病状。 该化合物可用作G蛋白偶联受体GPR-119的激动剂。 还包括药物组合物和治疗方法。
-
公开(公告)号：US20210094938A1
公开(公告)日：2021-04-01
申请号：US15733056
申请日：2018-11-12
申请人： Steven L. COLLETTI , Duane DEMONG , Kevin D. DYKSTRA , Zhiyong HU , Michael MILLER , Merck Sharp & Dohme Corp.
IPC分类号： C07D405/14 , A61P3/10
摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia Formula (I).
-
公开(公告)号：US10059667B2
公开(公告)日：2018-08-28
申请号：US15110894
申请日：2015-02-03
申请人： MERCK SHARP & DOHME CORP. , Harry Chobanian , Duane DeMong , Yan Guo , Zhiyong Hu , Michael Miller , Barbara Pio , Christopher W. Plummer , Dong Xiao , Cangming Yang , Rui Zhang
发明人： Harry Chobanian , Duane DeMong , Yan Guo , Zhiyong Hu , Michael Miller , Barbara Pio , Christopher W. Plummer , Dong Xiao , Cangming Yang
IPC分类号： C07D211/42 , A61K45/06 , A61K31/366 , A61K31/397 , A61K31/40 , A61K31/44 , C07D231/20 , A61K31/4985 , C07D401/04 , C07D239/52 , C07C217/52 , C07D205/04 , C07D491/056 , C07D265/30 , C07D207/08 , C07D207/10 , C07D207/12 , C07D209/52 , C07D209/54 , C07D211/22 , C07D213/30 , C07D213/64 , C07D213/65 , C07D213/69 , C07D307/86 , C07D307/88 , C07C59/72 , C07D205/12 , C07D213/647
CPC分类号： C07D211/42 , A61K31/366 , A61K31/397 , A61K31/40 , A61K31/44 , A61K31/4985 , A61K45/06 , C07C59/72 , C07C217/52 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/10 , C07D205/04 , C07D205/12 , C07D207/08 , C07D207/10 , C07D207/12 , C07D209/52 , C07D209/54 , C07D211/22 , C07D213/30 , C07D213/64 , C07D213/647 , C07D213/65 , C07D213/69 , C07D231/20 , C07D239/52 , C07D265/30 , C07D307/86 , C07D307/88 , C07D401/04 , C07D491/056 , A61K2300/00
摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号：US20160332968A1
公开(公告)日：2016-11-17
申请号：US15110894
申请日：2015-02-03
申请人： Harry CHOBANIAN , Duane DEMONG , Yan Guo , Zhiyong Hu , Barbara PIO , Christopher PLUMMER , Dong XIAO , Cangming YANG , Rui ZHANG , Merck Sharp & Dohme Corp. , Michael MILLER
发明人： Harry Chobanian , Duane DeMong , Yan Guo , Zhiyong Hu , Michael Miller , Barbara Pio , Christopher W. Plummer , Dong Xiao , Michael Yang
IPC分类号： C07D211/42 , C07D211/22 , C07D205/04 , C07D209/54 , C07D209/52 , C07D207/12 , C07D205/12 , C07C217/52 , C07D401/04 , C07D265/30 , C07C59/72 , C07D213/64 , C07D213/69 , C07D239/52 , C07D231/20 , C07D307/88 , C07D491/056 , C07D307/86 , C07D213/30 , C07D213/647 , C07D207/08
CPC分类号： C07D211/42 , A61K31/366 , A61K31/397 , A61K31/40 , A61K31/44 , A61K31/4985 , A61K45/06 , C07C59/72 , C07C217/52 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/10 , C07D205/04 , C07D205/12 , C07D207/08 , C07D207/10 , C07D207/12 , C07D209/52 , C07D209/54 , C07D211/22 , C07D213/30 , C07D213/64 , C07D213/647 , C07D213/65 , C07D213/69 , C07D231/20 , C07D239/52 , C07D265/30 , C07D307/86 , C07D307/88 , C07D401/04 , C07D491/056 , A61K2300/00
摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
摘要翻译： 结构式（I）的新型化合物及其药学上可接受的盐是G蛋白偶联受体40（GPR40）的激动剂，可用于治疗，预防和抑制G蛋白偶联受体 受体40.本发明的化合物可用于治疗2型糖尿病，以及通常与该疾病相关的病症，包括肥胖症和脂质疾病，例如混合或糖尿病性血脂异常，高脂血症，高胆固醇血症和 高甘油三酯血症
-
公开(公告)号：US11225471B2
公开(公告)日：2022-01-18
申请号：US15733056
申请日：2018-11-12
申请人： Steven L. Colletti , Duane DeMong , Kevin D. Dykstra , Zhiyong Hu , Michael Miller , Merck Sharp & Dohme Corp.
IPC分类号： C07D405/14 , A61P3/10
摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia Formula (I).
-
公开(公告)号：US10065945B2
公开(公告)日：2018-09-04
申请号：US15104537
申请日：2015-01-20
发明人： Richard Berger , Timothy A. Blizzard , Brian T. Campbell , Helen Y. Chen , John S. Debenham , Sunita V. Dewnani , Byron Dubois , Candido Gude , Zack Zhiqiang Guo , Bart Harper , Zhiyong Hu , Songnian Lin , Ping Liu , Ming Wang , Feroze Ujjainwalla , Jiayi Xu , Libo Xu , Rui Zhang
IPC分类号： C07D413/14 , C07D417/14 , C07D413/12 , C07D471/04 , C07D401/12
摘要： The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.028 秒)
